Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Value Vs. Values: ICER’s Review Of Opioid Abuse-Deterrent Formulations

Executive Summary

The Institute for Clinical & Economic Review is setting an appropriately broad scope in its review of the abuse-deterrent opioid class. But the project opens up a much larger question of how broadly to define value – and how to weigh non-economic values – in cost-effectiveness reviews.

You may also be interested in...



Abuse-Deterrent Opioids: ICER Value Analysis Could Reinforce Coverage Restrictions

Draft report concludes that added cost of abuse-deterrent opioids is not outweighed by reductions to health care system costs resulting from their use.

Abuse-Deterrent Opioids Effectiveness, Value To Get ICER Review

Pending arrival of several new products prompts evaluation of class, ICER CSO Dan Ollendorf explains; availability of both abuse-deterrent and non-abuse-deterrent drugs among challenging issues.

ICER Report Questions Cost-Effectiveness Of PD-1 Drugs In Lung Cancer

ICER report finds EGFR inhibitors are cost-effective in first-line non-small cell lung cancer, but PD-1/L1 inhibitors from Bristol, Merck and Roche may fall short in second-line treatment.

Related Content

Topics

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel